Company Performance - Pacific Biosciences of California (PACB) closed at $1.50, with a daily increase of +1.35%, outperforming the S&P 500's gain of 0.28% [1] - The stock has increased by 27.59% over the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Expectations - Analysts expect Pacific Biosciences to report earnings of -$0.18 per share, reflecting a year-over-year growth of 10% [2] - The revenue forecast for the upcoming quarter is $36.46 million, indicating a growth of 1.26% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at -$0.64 per share and revenue at $155.12 million, showing changes of +22.89% and +0.72% respectively from the previous year [3] Analyst Sentiment - Recent adjustments to analyst estimates indicate positive sentiment towards Pacific Biosciences' business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses stock performance based on estimate changes, currently ranks Pacific Biosciences as 1 (Strong Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 173, placing it in the bottom 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Esti ...

Group 1 - Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, with a +1.72% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.38% [1] - The company has seen a 5.45% increase in its share price over the past month, while the Medical sector gained 4.64% and the S&P 500 gained 6.6% during the same period [1] Group 2 - The upcoming financial results for Pacific Biosciences are anticipated to show an EPS of -$0.18, reflecting a 10% growth compared to the same quarter last year, with a revenue forecast of $36.46 million, indicating a 1.26% growth year-over-year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$0.64 per share and revenue of $155.12 million, representing shifts of +22.89% and +0.72% respectively from the previous year [3] Group 3 - Recent modifications to analyst estimates for Pacific Biosciences indicate shifting dynamics in short-term business patterns, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses estimate changes, currently places Pacific Biosciences at a Zacks Rank of 3 (Hold), with an 8.36% increase in the consensus EPS estimate over the last 30 days [6] Group 4 - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries, indicating relative underperformance compared to higher-ranked industries [7]

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Sinc ...

Company Performance - Pacific Biosciences of California (PACB) closed at $1.11, reflecting a -1.77% change from the previous day, underperforming the S&P 500's gain of 0.58% [1] - Over the past month, PACB shares have decreased by 4.24%, compared to a 5.22% loss in the Medical sector and a 0.84% loss in the S&P 500 [1] Upcoming Earnings - The company is expected to report an EPS of -$0.19, which represents a 26.92% increase from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $35 million, indicating a decline of 9.82% from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$0.71 and revenue of $158.74 million, reflecting changes of +14.46% and +3.07% respectively from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Pacific Biosciences are important as they reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Consensus EPS estimate has decreased by 0.95% in the past month, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 54, placing it in the top 22% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.17, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.67%. Meanwhile, the Dow experienced a rise of 1.07%, and the technology-dominated Nasdaq saw an increase of 2.5%.The the stock of maker of genetic analysis technology has fallen by 10.69% in the past month, lagging the Medical sector's loss of 9.34% and the S&P 500's loss of 6.57%.Market participants will be c ...